{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:43:06Z","timestamp":1768527786263,"version":"3.49.0"},"reference-count":229,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1053\/j.jvca.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T10:11:29Z","timestamp":1749377489000},"page":"3122-3139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications"],"prefix":"10.1053","volume":"39","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.06.015_bib0001","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1053\/j.jvca.2025.05.010","article-title":"Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransporter type 2 inhibitors, Part 1: Efficacy in heart failure and myocardial infarction","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardiothoracic Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0002","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0003","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: A matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12325-023-02652-5","article-title":"Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors","volume":"41","author":"Verma","year":"2024","journal-title":"Adv Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0007","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3390\/ijms25052484","article-title":"Potential mechanisms of the protective effects of the cardiometabolic drugs type-2 sodium-glucose transporter inhibitors and glucagon-like peptide-1 receptor agonists in heart failure","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/10742484251323428","article-title":"Direct cardiac mechanisms of the sodium glucose co-transporter 2 inhibitor class","volume":"30","author":"Hopkins","year":"2025","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized controlled trials with 22528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.06.015_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0011","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0012","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0013","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor alpha-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1053\/j.jvca.2025.06.015_bib0014","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0016","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibitors interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2025.06.015_bib0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","article-title":"Empagliflozin restores the integrity of the endothelial glycocalyx in vitro","volume":"459","author":"Cooper","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"10.1053\/j.jvca.2025.06.015_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0019","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/ijms26052103","article-title":"Sodium-glucose transporter-2 inhibitors (SGLT2i) and myocardial ischemia: Another compelling reason to consider these agents regardless of diabetes","volume":"26","author":"Piccirillo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"10.1053\/j.jvca.2025.06.015_bib0021","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fphar.2019.00362","article-title":"Canagliflozin inhibits human endothelial cell proliferation and tube formation","volume":"10","author":"Behnammenesh","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0022","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammenesh","year":"2020","journal-title":"Redox Biol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0023","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.111.181784","article-title":"Compound C inhibits vascular smooth muscle cell proliferation in an AMP-activated protein kinase-independent fashion","volume":"338","author":"Peyton","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-019-0947-5","article-title":"Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling","volume":"18","author":"Mori","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.06.015_bib0027","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (sodium-glucose cotransporter 2) inhibition reduces Ang II (angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: A post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0029","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.124.068788","article-title":"Dapagliflozin enhances arterial and venous compliance during exercise in heart failure with preserved ejection fraction: Insights from the CAMEO-DAPA trial","volume":"150","author":"Tada","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with reduced ejection fraction: A secondary analysis of a randomized controlled trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0031","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0032","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: A systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0033","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10741-024-10465-z","article-title":"Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: A mini-review","volume":"30","author":"Alyaydin","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.06.015_bib0034","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0035","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0036","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0037","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0038","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0039","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective congestion following SGLT2i inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0041","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function, and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0042","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1053\/j.jvca.2025.06.015_bib0043","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"10.1053\/j.jvca.2025.06.015_bib0044","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0045","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes and antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0046","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0047","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0048","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0049","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.0000000000000269","article-title":"Empagliflozin in heart failure: Regional nephron sodium handling effects","volume":"35","author":"Rao","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0050","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0051","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0052","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0053","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0054","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2025.06.015_bib0056","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","article-title":"Cardiac insulin resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy","volume":"6","author":"Zhang","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0057","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014An engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0058","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006240","article-title":"Myocardial energetics in heart failure with preserved ejection fraction","volume":"12","author":"AbouEzzeddine","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0059","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: Novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0061","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","article-title":"Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency","volume":"115","author":"Ho","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0062","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: The double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0063","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","article-title":"Metabolic effects of the SGLT2 inhibitor dapagliflozin in heart failure across the spectrum of ejection fraction","volume":"17","author":"Selvaraj","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jchf.2024.02.018","article-title":"Targeted metabolomic profiling of dapagliflozin in heart failure with preserved ejection fraction: The PRESERVED-HF trial","volume":"12","author":"Selvaraj","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0066","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12933-024-02221-2","article-title":"Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: A post hoc analysis of the EMMY trial","volume":"23","author":"Aziz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0067","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/ehf2.13406","article-title":"Design and rationale of the EMPA-VISION trial: Investigating the metabolic effects of empagliflozin in patients with heart failure","volume":"8","author":"Hundertmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0068","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: The randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0069","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.2337\/db21-0270","article-title":"Empagliflozin treatment is associated with improvements in cardiac energetics and function and reductions in myocardial cell volume in patients with type 2 diabetes","volume":"70","author":"Thirunavukarasu","year":"2021","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.yjmcc.2013.02.007","article-title":"Regulation of the cardiac Na+\/H+ exchange in health and disease","volume":"61","author":"Wakabayashi","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0071","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0072","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0073","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0074","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors\u2014Does it all come down to Na+?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0075","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes","volume":"4","author":"Iborra-Egea","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0076","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: Empagliflozin does not inhibit Na+\/H+ exchanger 1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0077","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: Regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1053\/j.jvca.2025.06.015_bib0078","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCRESAHA.116.303805","article-title":"The role of autophagy in vascular biology","volume":"116","author":"Nussenzweig","year":"2015","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0079","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0081","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc19-1410","article-title":"Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming","volume":"53","author":"Avogaro","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0082","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0083","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: Mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0084","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","article-title":"Chronic heart failure and inflammation: What do we really know?","volume":"119","author":"Dick","year":"2016","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0086","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","article-title":"The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure","volume":"21","author":"Briasoulis","year":"2016","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.06.015_bib0087","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0088","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac myofibroblasts: Novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0089","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces activation of Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0090","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0091","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: Molecular activation and regulation to therapeutics","volume":"19","author":"Swenson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0092","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","article-title":"The importance of NLRP3 inflammasome in heart failure","volume":"21","author":"Butts","year":"2015","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820541","article-title":"Canagliflozin ameliorates NLRP3 inflammasome-mediated inflammation through NF-kB signaling and upregulating Bif-1","volume":"13","author":"Niu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0094","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-kB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollah","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0095","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2025.06.015_bib0096","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0097","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic neuropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0098","doi-asserted-by":"crossref","first-page":"8777","DOI":"10.3390\/ijms23158777","article-title":"Canagliflozin inhibits human endothelial cell inflammation through the induction of heme oxygenase-1","volume":"23","author":"Peyton","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0099","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/biom11040589","article-title":"Heme oxygenase-1 signaling and redox homeostasis in pathophysiological conditions","volume":"11","author":"Consoli","year":"2021","journal-title":"Biomolecules"},{"key":"10.1053\/j.jvca.2025.06.015_bib0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ahj.2007.03.019","article-title":"Human epicardial adipose tissue: A review","volume":"153","author":"Sacks","year":"2007","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0101","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/ATVBAHA.112.300829","article-title":"Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis","volume":"33","author":"Shimabukuro","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0102","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/cvr\/cvu045","article-title":"Epicardial adipose tissue and atrial fibrillation","volume":"102","author":"Hatem","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0103","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013104","article-title":"Statins reduce epicardial adipose tissue attenuation independent of lipid lowering: A potential pleiotropic effect","volume":"8","author":"Raggi","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.06.015_bib0104","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.numecd.2017.05.010","article-title":"Novel atherogenic pathways from the differential transcriptome analysis of diabetic epicardial adipose tissue","volume":"27","author":"Camarena","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1053\/j.jvca.2025.06.015_bib0105","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/oby.22798","article-title":"Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity","volume":"28","author":"Iacobellis","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.jvca.2025.06.015_bib0106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0107","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1053\/j.jvca.2025.06.015_bib0108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12933-024-02298-9","article-title":"Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure","volume":"23","author":"Kasperova","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0109","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: Modulation of insulin resistance, inflammatory cytokine production, and differentiation ability","volume":"114","author":"Diaz-Rodriguez","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.06.015_bib0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric acid and cardiovascular disease: An update","volume":"11","author":"Muiesan","year":"2016","journal-title":"Eur Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0111","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0112","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0113","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.0000066420.36123.35","article-title":"Uric acid predicts clinical outcomes in heart failure: Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology","volume":"107","author":"Hare","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ajh.2010.111","article-title":"Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension","volume":"24","author":"Vlachopoulos","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.jvca.2025.06.015_bib0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/01.HYP.0000161184.10873.ea","article-title":"Serum uric acid and target organ damage in primary hypertension","volume":"45","author":"Viazzi","year":"2005","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2025.06.015_bib0116","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/jhh.2010.120","article-title":"Uric acid levels, left ventricular mass and geometry in newly diagnosed, never treated hypertension","volume":"25","author":"Xaplanteris","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1053\/j.jvca.2025.06.015_bib0117","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"37","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1053\/j.jvca.2025.06.015_bib0118","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0119","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0120","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: The EMPEROR-preserved trial","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0121","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 inhibition with empagliflozin increases circulation provascular progenitor cells in people with type 2 diabetes mellitus","volume":"30","author":"Hess","year":"2019","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0122","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db20-1045","article-title":"Inhibition of SGLT2 rescues bone marrow cell traffic for vascular repair: Role of glucose control and ketogenesis","volume":"70","author":"Albiero","year":"2021","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0123","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dbi21-0025","article-title":"Heal thyself: SGLT2 inhibition limits regenerative cell exhaustion and heals damaged vessels","volume":"70","author":"Hess","year":"2021","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0124","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"Effect of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177355","article-title":"Sodium-glucose cotransporter 2 inhibitor empagliflozin enhances autophagy and reverses remodeling in hearts with large, old myocardial infarctions","volume":"992","author":"Endo","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: A meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.jvca.2025.06.015_bib0127","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: A review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1053\/j.jvca.2025.06.015_bib0128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.06.015_bib0129","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1111\/dom.16385","article-title":"A review of safety of sodium-glucose co-transporter 2 inhibitors","volume":"27","author":"O\u2019Hara","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0130","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","article-title":"Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors","volume":"185","author":"Shin","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.06.015_bib0132","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/MS9.0000000000002903","article-title":"Cardiovascular outcomes and safety assessment of SGLT2i on heart failure patients: A systematic review and meta-analysis","volume":"87","author":"Waseem","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1053\/j.jvca.2025.06.015_bib0133","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0134","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0136","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systemic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0137","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0138","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0139","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0140","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0141","doi-asserted-by":"crossref","first-page":"bqaa080","DOI":"10.1210\/endocr\/bqaa080","article-title":"Dapagliflozin does not directly affect human alpha or beta cells","volume":"161","author":"Dai","year":"2020","journal-title":"Endocrinology"},{"key":"10.1053\/j.jvca.2025.06.015_bib0142","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2025.06.015_bib0143","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0144","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative risk of genital infections associated with sodium-glucose co-transporter 2 inhibitors","volume":"21","author":"Dave","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0145","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0146","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0147","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1213\/ANE.0000000000002377","article-title":"Perioperative considerations for the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"126","author":"Peacock","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.06.015_bib0148","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1213\/ANE.0000000000002740","article-title":"New diabetes medications raise new perioperative concerns for the anesthesiologist","volume":"126","author":"DeCou","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.06.015_bib0149","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14740338.2020.1694659","article-title":"Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: Interim analysis from a post-marketing surveillance survey","volume":"19","author":"Kaku","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.jvca.2025.06.015_bib0150","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ejhf.2584","article-title":"Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: A systematic review and meta-analysis","volume":"24","author":"Vukadinovic","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.06.015_bib0151","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1093\/ndt\/gfz252","article-title":"Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?","volume":"35","author":"Neuen","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jvca.2025.06.015_bib0152","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/HCO.0000000000000704","article-title":"Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: Clinical pearls for in-hospital initiation, in-hospital management, and postdischarge","volume":"35","author":"Mazer","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0153","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: A pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0154","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.06.015_bib0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0156","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: Cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"10.1053\/j.jvca.2025.06.015_bib0157","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: Real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0158","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.amjcard.2023.06.016","article-title":"Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide Veterans Health Administration observational cohort study","volume":"201","author":"Patil","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0159","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0161","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc24-1546","article-title":"Use of SGLT2i versus DDP-4i as an add-on therapy and risk of PAD-related surgical events (amputation, stent placement, or vascular surgery): A cohort study in veterans with diabetes","volume":"48","author":"Griffin","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0162","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/dom.14091","article-title":"The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial","volume":"22","author":"Arnott","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0163","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture risk after initiation of use of canagliflozin: A cohort study","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0164","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor antagonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 inhibitors and the risk of hospitalization for Fournier\u2019s gangrene: A nested case-control study","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0166","unstructured":"US Food and Drug Administration. FDA strengthens kidney warning for medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Fargixa, Xigduo XR). https:\/\/www.fda.gov\/media\/98683\/download. Published 2016. Accessed May 12, 2025."},{"key":"10.1053\/j.jvca.2025.06.015_bib0167","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jvca.2025.06.015_bib0168","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.918167","article-title":"Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: A propensity-matched analysis","volume":"9","author":"Hua","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0169","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2025.06.015_bib0170","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP-DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0171","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium: Impact of diabetes on the effects of sodium-glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.06.015_bib0172","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/jcm13061748","article-title":"Risk of diabetic ketoacidosis associated with sodium glucose cotransporter-2 inhibitors: A network meta-analysis and meta-regression","volume":"13","author":"Sridharan","year":"2024","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0173","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.japh.2023.10.010","article-title":"Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis","volume":"64","author":"Al-Hindi","year":"2024","journal-title":"J Am Pharm Assoc"},{"key":"10.1053\/j.jvca.2025.06.015_bib0174","article-title":"Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: A meta-analysis of cohort studies","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5694\/mja2.52067","article-title":"Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes","volume":"219","author":"Raven","year":"2023","journal-title":"Med J Aust"},{"key":"10.1053\/j.jvca.2025.06.015_bib0176","article-title":"Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: A case report","volume":"16","author":"Seki","year":"2022","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2025.06.015_bib0177","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bja.2023.11.015","article-title":"Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: Is there a perioperative risk of euglycemic ketoacidosis?","volume":"132","author":"Ruste","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0178","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemia ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0179","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc23-1903","article-title":"SGLT2 inhibitor-induced ketoacidosis in a patient without diabetes","volume":"47","author":"Hayes","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0002-9629(15)41700-8","article-title":"Review: Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome","volume":"311","author":"Umpierrez","year":"1996","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.jvca.2025.06.015_bib0181","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diabet.2017.09.006","article-title":"Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes","volume":"44","author":"Min","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0182","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/dom.13224","article-title":"Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin","volume":"20","author":"Polidori","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0183","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.bja.2021.03.023","article-title":"Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: Single centre experience and recommendations","volume":"127","author":"Wang","year":"2021","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0184","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bja.2023.06.063","article-title":"Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: A single-centre retrospective analysis","volume":"131","author":"Steinhorn","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0185","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.jvca.2025.06.015_bib0186","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/anae.16461","article-title":"The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: A narrative review","volume":"80","author":"Stewart","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0187","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4239\/wjd.v14.i8.1314","article-title":"Sodium-glucose cotransporter-2 inhibitors induced euglycemia diabetic ketoacidosis: A meta summary of case reports","volume":"14","author":"Juneja","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0188","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1053\/j.jvca.2025.06.015_bib0189","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.828649","article-title":"New diabetic medication sodium-glucose cotransporter-2 inhibitors can induce euglycemic ketoacidosis and mimic surgical diseases: A case report and review of literature","volume":"9","author":"Kietaibl","year":"2022","journal-title":"Front Surg"},{"key":"10.1053\/j.jvca.2025.06.015_bib0190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study","volume":"173","author":"Douras","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0191","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0310057X19892988","article-title":"An analysis of the Australian Therapeutic Goods Administration Database of Adverse Event Notification of diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors in surgical patients","volume":"48","author":"Thirunavukarasu","year":"2020","journal-title":"Anaesth Intensive Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0192","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0193","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"10.1053\/j.jvca.2025.06.015_bib0194","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0195","article-title":"Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: A focused review of pathophysiology, risk factors, and triggers","volume":"13","author":"Somagutta","year":"2021","journal-title":"Cureus"},{"key":"10.1053\/j.jvca.2025.06.015_bib0196","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12630-017-1019-5","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting","volume":"65","author":"Peacock","year":"2018","journal-title":"Can J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0197","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0310057X1804600202","article-title":"The good, the bad, and the ugly: Sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes","volume":"46","author":"Kerridge","year":"2018","journal-title":"Anaesth Intensive Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0198","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2025.06.015_bib0199","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2025.06.015_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101071","article-title":"SGLT2 is not expressed in pancreatic alpha- and beta-cells and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans","volume":"42","author":"Chae","year":"2020","journal-title":"Mol Metab"},{"key":"10.1053\/j.jvca.2025.06.015_bib0201","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: Pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/03007995.2025.2458538","article-title":"Perioperative and perioprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: Narrative review and the STOP-GAP and STOP DKA-2 algorithms","volume":"41","author":"Goldenberg","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.jvca.2025.06.015_bib0203","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2025.06.015_bib0204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: A systematic review","volume":"123","author":"Thirunavukarasu","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","article-title":"Drug-drug interactions with sodium-glucose cotransporter type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2025.06.015_bib0206","unstructured":"US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Published 2022. Accessed May 10, 2025."},{"key":"10.1053\/j.jvca.2025.06.015_bib0207","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0208","first-page":"1153","article-title":"2022 Canadian Cardiovascular Society guideline for the use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0209","unstructured":"Centre for Perioperative Care. Perioperative care of people with diabetes undergoing surgery. https:\/\/cpoc.org.uk\/guidelines-and-resources\/guidelines\/guideline-diabetes. Published 2021. Accessed May 10, 2025."},{"key":"10.1053\/j.jvca.2025.06.015_bib0210","unstructured":"UK Clinical Pharmacy Association. Handbook of perioperative medicines. https:\/\/periop-handbook.ukclinicalpharmacy.org. Published 2023. Accessed May 10, 2025."},{"key":"10.1053\/j.jvca.2025.06.015_bib0211","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2025.06.015_bib0212","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0213","unstructured":"Australian Diabetes Society. Periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use in people with diabetes. https:\/\/www.diabetessociety.com.au\/wp-content\/uploads\/2023\/05\/ADS-ADEA-ANZCA-NZSSD_DKA_SGLT2i_Alert_Ver-May-2023.pdf. Published 2023. Accessed May 10, 2025."},{"key":"10.1053\/j.jvca.2025.06.015_bib0214","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/j.ajkd.2022.10.012","article-title":"Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: A modified Delphi process","volume":"81","author":"Watson","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jvca.2025.06.015_bib0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: A systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0216","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1053\/j.jvca.2025.02.030","article-title":"Retrospective chart review of euglycemic diabetic ketoacidosis rates and outcomes postimplementation of sodium glucose cotransporter 2 inhibitor use stoppage 5 days before open heart surgery","volume":"39","author":"Auerbach","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0217","doi-asserted-by":"crossref","first-page":"e5057","DOI":"10.1002\/ccr3.5057","article-title":"Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy","volume":"9","author":"Bobrowski","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1053\/j.jvca.2025.06.015_bib0218","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bja.2023.12.015","article-title":"Perioperative use of glucose-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus","volume":"132","author":"Dhatariya","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0219","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/ACO.0000000000000674","article-title":"Sodium-glucose cotransporter-2 inhibitors: An overview and perioperative implications","volume":"32","author":"Bardia","year":"2019","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","article-title":"A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes","volume":"46","author":"Liu","year":"2023","journal-title":"Drug Saf"},{"key":"10.1053\/j.jvca.2025.06.015_bib0221","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors","volume":"37","author":"Auerbach","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0222","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/EJA.0000000000002090","article-title":"Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery: The impact of SGLT2 inhibitor use: A retrospective cohort study","volume":"42","author":"Brekke","year":"2025","journal-title":"Eur J Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.06.015_bib0223","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.jvca.2023.10.011","article-title":"Perioperative management of patients receiving sodium-glucose cotransporter 2 inhibitors: Development of a clinical guideline at a large academic medical center","volume":"38","author":"Raiten","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0224","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/imj.15366","article-title":"An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines","volume":"51","author":"Fookeerah","year":"2021","journal-title":"Intern Med J"},{"key":"10.1053\/j.jvca.2025.06.015_bib0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","article-title":"Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis","volume":"160","author":"Dixit","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1053\/j.jvca.2025.06.015_bib0226","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00540-024-03335-3","article-title":"Incidence of sodium-glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: A prospective cohort study","volume":"38","author":"Seki","year":"2024","journal-title":"J Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","article-title":"Risk of perioperative discontinuation of SGLT2 inhibitors","volume":"133","author":"Oosterom-Eijmael","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0228","first-page":"1590","article-title":"CON: Should patients taking sodium-glucose co-transporter 2 inhibitors be dropped from the elective surgical program?","volume":"38","author":"Wohlrab","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.06.015_bib0229","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025004732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025004732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:42:03Z","timestamp":1760139723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025004732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":229,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1053077025004732"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.06.015","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}